Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-09T14:37:39.597Z Has data issue: false hasContentIssue false

Chapter 32 - Lysosomal storage disorders

from Section IV - Metabolic liver disease

Published online by Cambridge University Press:  05 March 2014

T. Andrew Burrow
Affiliation:
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
Gregory A. Grabowski
Affiliation:
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA
Frederick J. Suchy
Affiliation:
University of Colorado Medical Center
Ronald J. Sokol
Affiliation:
University of Colorado Medical Center
William F. Balistreri
Affiliation:
University of Cincinnati College of Medicine
Get access

Summary

Introduction

Lysosomes are membrane bound cellular organelles that contain multiple hydrolases needed for the digestion of various macromolecules including mucopolysaccharides, glycosphingolipids and oligosaccharides. The lysosomal storage diseases are a group of over 40 diseases that are characterized by defective lysosomal function, leading to an accumulation of specific substrates within the lysosomes and eventual impairment of cellular function. A schematic of the lysosomal system enzyme trafficking and substrate accumulation is shown in Figure 32.1.

These diseases are classified by the nature of the stored material that results from the defects in selected lysosomal enzymes, their cofactors, and/or enzyme or substrate transport (Table 32.1). The lysosomal storage diseases are heterogeneous, progressive, multisystem diseases that have a spectrum of ages of onset, severity, rate of progression, and organ involvement. Lysosomal storage diseases have significant morbidity and mortality in the absence of effective treatment. The majority of these diseases are autosomal recessive and, although individually rare, the combined birth prevalence is approximately 1 in 7 000 live births [2]. The diseases are traditionally diagnosed biochemically, but in many cases may also be confirmed molecularly by the identification of pathogenic mutations in one or both copies (X-linked conditions or autosomal recessive, respectively) of the specific genes.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Muenzer, J, Fisher, A. Advances in the treatment of mucopolysaccharidosis type I. N Engl J Med 2004;350:1932–1934.CrossRefGoogle ScholarPubMed
Poorthuis, BJ, Wevers, RA, Kleijer, WJ, et al. The frequency of lysosomal storage diseases in the Netherlands. Hum Genet 1999;105(1–2):151–156.CrossRefGoogle ScholarPubMed
Grabowski, GA, Petsko, GA, Kolodny, EH. Gaucher disease. In Valle D, Beaudet AL, Vogelstein B, et al. (eds.) The Online Metabolic & Molecular Bases of Inherited Disease. (, accessed 22 July 2013).
James, SP, Stromeyer, FW, Chang, C, Barranger, JA. Liver abnormalities in patients with Gaucher’s disease. Gastroenterology 1981;80:126–133.Google ScholarPubMed
Barbier, C, Devisme, L, Dobbelaere, D, et al. Neonatal cholestasis and infantile Gaucher disease: a case report. Acta Paediatr 2002;91:1399–1401.CrossRefGoogle ScholarPubMed
Weinreb, NJ, Charrow, J, Andersson, HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112–119.CrossRefGoogle ScholarPubMed
Lukina, E, Watman, N, Arreguin, EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 2010;116:4095–4098.CrossRefGoogle ScholarPubMed
Meikle, PJ, Hopwood, JJ, Clague, AE, Carey, WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249–254.CrossRefGoogle ScholarPubMed
Schuchman, EH, Desnick, RJ. Niemann–Pick disease types A and B: acid sphingomyelinase deficiencies. In Valle D, Beaudet AL, Vogelstein B, et al. (eds.) The Online Metabolic & Molecular Bases of Inherited Disease. (, accessed 22 July 2013).
Wasserstein, MP, Desnick, RJ, Schuchman, EH, et al. The natural history of type B Niemann–Pick disease: results from a 10-year longitudinal study. Pediatrics 2004;114:e672–e677.CrossRefGoogle ScholarPubMed
Takahashi, T, Akiyama, K, Tomihara, M, et al. Heterogeneity of liver disorder in type B Niemann–Pick disease. Hum Pathol 1997;28:385–388.CrossRefGoogle ScholarPubMed
Victor, S, Coulter, JB, Besley, GT, et al. Niemann–Pick disease: sixteen-year follow-up of allogeneic bone marrow transplantation in a type B variant. J Inherit Metab Dis 2003;26:775–785.CrossRefGoogle Scholar
Levade, T, Sandhoff, K, Schulze, H, Medin, JA. Acid Ceramidase Deficiency: Farber Lipogranulomatosis. In Valle D, Beaudet AL, Vogelstein B, et al. (eds.) The Online Metabolic & Molecular Bases of Inherited Disease. (, accessed 22 July 2013).
Kattner, E, Schafer, A, Harzer, K. Hydrops fetalis: manifestation in lysosomal storage diseases including Farber disease. Eur J Pediatr 1997;156:292–295.CrossRefGoogle ScholarPubMed
Yeager, AM, Uhas, KA, Coles, CD, et al. Bone marrow transplantation for infantile ceramidase deficiency (Farber disease). Bone Marrow Transplant 2000;26:357–363.CrossRefGoogle Scholar
Vormoor, J, Ehlert, K, Groll, AH, et al. Successful hematopoietic stem cell transplantation in Farber disease. J Pediatr 2004;144:132–134.CrossRefGoogle ScholarPubMed
Suzuki, Y, Nanba, E, Matsuda, J, Higaki, K, Oshima, A. B-Galactosidase deficiency (B-galactosidosis): GM1 gangliosidosis and morquio B disease. In Valle D, Beaudet AL, Vogelstein B, et al. (eds.) The Online Metabolic & Molecular Bases of Inherited Disease. (, accessed 22 July 2013).
Vanier, MT, Millat, G. Niemann–Pick disease type C. Clin Genet 2003;64:269–281.CrossRefGoogle ScholarPubMed
Vanier, MT. Niemann–Pick disease type C. Orphanet J Rare Dis 2010;5:16.CrossRefGoogle ScholarPubMed
Patterson, MC, Vanier, MT, Suzuki, K, et al. Niemann–Pick disease Type C: A lipid trafficking disorder. In Valle D, Beaudet AL, Vogelstein B, et al. (eds.) The Online Metabolic & Molecular Bases of Inherited Disease. (, accessed 22 July 2013).
Patterson, M. Niemann–Pick disease type C. In Pagon, RA, Bird, TD, Dolan, CR, Stephens, K (eds.) GeneReviews. Seattle, WA: University of Washington, Seattle, 1993– (website, updated July 2008; accessed March 13, 2012).Google ScholarPubMed
Kelly, DA, Portmann, B, Mowat, AP, Sherlock, S, Lake, BD. Niemann–Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease. J Pediatr 1993;123:242–247.CrossRefGoogle ScholarPubMed
Gilbert, EF, Callahan, J, Viseskul, C, Opitz, JM. Niemann–Pick disease type C. Pathological, histochemical, ultrastructural and biochemical studies. Eur J Pediatr 1981;136:263–274.CrossRefGoogle ScholarPubMed
Yerushalmi, B, Sokol, RJ, Narkewicz, MR, et al. Niemann–Pick disease type C in neonatal cholestasis at a North American Center. J Pediatr Gastroenterol Nutr 2002;35:44–50.CrossRefGoogle Scholar
Zervas, M, Somers, KL, Thrall, MA, Walkley, SU. Critical role for glycosphingolipids in Niemann–Pick disease type C. Curr Biol 2001;11:1283–1287.CrossRefGoogle ScholarPubMed
Wraith, JE, Vecchio, D, Jacklin, E, et al. Miglustat in adult and juvenile patients with Niemann–Pick disease type C: long-term data from a clinical trial. Mol Genet Metab 2010;99:351–357.CrossRefGoogle ScholarPubMed
Ashe, KM, Bangari, D, Li, L, et al. Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease. PLOS One 2011;6:e21758.CrossRefGoogle Scholar
Thomas, GH. Disorders of glycoprotein degradation: α-mannosidosis, B-mannosidosis, fucosidosis, and sialidosis. In Valle D, Beaudet AL, Vogelstein B, et al. (eds.) The Online Metabolic & Molecular Bases of Inherited Disease. (, accessed 22 July 2013).
Willems, PJ, Gatti, R, Darby, JK, et al. Fucosidosis revisited: a review of 77 patients. Am J Med Genet 1991;38:111–131.CrossRefGoogle ScholarPubMed
Freitag, F, Blumcke, S, Spranger, J. Hepatic ultrastructure in mucolipidosis I (lipomucopolysaccharidosis). Virchows Arch B Cell Pathol 1971;7:189–204.Google Scholar
Vellodi, A, Cragg, H, Winchester, B, et al. Allogeneic bone marrow transplantation for fucosidosis. Bone Marrow Transplant 1995;15:153–158.Google ScholarPubMed
Monus, Z, Konyar, E, Szabo, L. Histomorphologic and histochemical investigations in mannosidosis. A light and electron microscopic study. Virchows Arch B Cell Pathol 1977;26:159–173.Google ScholarPubMed
d’Azzo, A, Andria, G, Strisciuglio, P, Galactosialidosis, Galjaard H.. In Valle D, Beaudet AL, Vogelstein B, et al. (eds.) The Online Metabolic & Molecular Bases of Inherited Disease. (, accessed 22 July 2013).
van der Spoel, A, Bonten, E, d’Azzo, A. Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein/cathepsin A. EMBO J 1998;17:1588–1597.CrossRefGoogle ScholarPubMed
Hirschhorn, R, Reuser, AJJ. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. In Valle D, Beaudet AL, Vogelstein B, et al. (eds.) The Online Metabolic & Molecular Bases of Inherited Disease (, accessed 22 July 2013).
van den Hout, HM, Hop, W, van Diggelen, OP, et al. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332–340.CrossRefGoogle ScholarPubMed
Leslie, N, Tinkle, B. Glycogen storage disease type II (Pompe disease). In Pagon, RA, Bird, TD, Dolan, CR, Stephens, K (eds.) GeneReviews. Seattle, WA: University of Washington, Seattle, 1993– (website, updated August 2010).Google ScholarPubMed
Kishnani, PS, Howell, RR. Pompe disease in infants and children. J Pediatr 2004;144(5 Suppl):S35–43.CrossRefGoogle ScholarPubMed
Hagemans, ML, Winkel, LP, Van Doorn, PA, et al. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients. Brain. 2005;128(Pt 3):671–677.CrossRefGoogle ScholarPubMed
Kishnani, PS, Corzo, D, Leslie, ND, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009;66:329–335.CrossRefGoogle ScholarPubMed
Assmann, G, Seedorf, U. Acid Lipase deficiency: Wolman disease and cholesteryl ester storage disease. In Valle D, Beaudet AL, Vogelstein B, et al. (eds.) The Online Metabolic & Molecular Bases of Inherited Disease. (, accessed 22 July 2013).
Muntoni, S, Wiebusch, H, Jansen-Rust, M, et al. Prevalence of cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol 2007;27:1866–1868.CrossRefGoogle ScholarPubMed
Grabowski, G, Bove, K, Du, H. Lysosomal acid lipase deficiencies: Wolman disease and cholesteryl ester storage disease. In Walker, WA, Goulet, OJ, Kleinman, RE (eds.) Pediatric Gastrointestinal Disease: Pathophysiology, Diagnosis and Management. Hamilton, Ontario: Decker, 2004, pp. 1429–1439.Google Scholar
Krivit, W, Freese, D, Chan, KW, Kulkarni, R. Wolman’s disease: a review of treatment with bone marrow transplantation and considerations for the future. Bone Marrow Transplant 1992;10(Suppl 1):97–101.Google ScholarPubMed
Valle, D, Beaudet, AL, Vogelstein, B, et al. (eds.). Online Metabolic and Molecular Bases of Inherited Disease, 2006 (, updated March 2011, accessed 10 November 2013).
Parfrey, NA, Hutchins, GM. Hepatic fibrosis in the mucopolysaccharidoses. Am J Med 1986;81:825–829.CrossRefGoogle ScholarPubMed
Kornfeld, S, Sly, WS. I-cell disease and pseudo-Hurler polydystrophy: disorders of lysosomal enzyme phosphorylation and localization. In Valle D, Beaudet AL, Vogelstein B, et al. (eds.) The Online Metabolic & Molecular Bases of Inherited Disease. (, accessed 22 July 2013).
Pinto, R, Caseiro, C, Lemos, M, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 2004;12:87–92.CrossRefGoogle ScholarPubMed
Kelly, TE, Thomas, GH, Taylor, HA, et al. Mucolipidosis III (pseudo-Hurler polydystrophy): Clinical and laboratory studies in a series of 12 patients. Johns Hopkins Med J 1975;137:156–175.Google Scholar
Cathey, SS, Leroy, JG, Wood, T, et al. Phenotype and genotype in mucolipidoses II and III alpha/beta: a study of 61 probands. J Med Genet 2010;47:38–48.CrossRefGoogle ScholarPubMed
Kenyon, KR, Sensenbrenner, JA, Wyllie, RG. Hepatic ultrastructure and histochemistry in mucolipidosis II (I-cell disease). Pediatr Res 1973;7:560–568.CrossRefGoogle Scholar
Hopwood, JJ, Ballabio, A. Multiple sulfatase deficiency and the nature of the sulfatase family. In Valle D, Beaudet AL, Vogelstein B, et al. (eds.) The Online Metabolic & Molecular Bases of Inherited Disease. (, accessed 22 July 2013).

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×